Tempus‑Personalis Deal: $1.7 B AI‑Driven Leap into Precision OncologyTempus’s $1.7B all‑stock buy of Personalis unlocks $20B MRD market, fusing AI diagnostics with liquid biopsy for next‑gen precision oncology.PERSONALIS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 21/07/2026, 21:30 3 minutes to read
